Erlotinib

American Journal of Cancer

Volumn 4, Issue 4, 2005, Pages 247-252

  Robinson, Dean M ^a   Keating, Gillian M ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBAMAZEPINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROMYCIN; GEMCITABINE; ITRACONAZOLE; KETOCONAZOLE; PHENOBARBITAL; PHENYTOIN; PLATINUM; QUINAZOLINE DERIVATIVE; RIFAMPICIN; TAXANE DERIVATIVE; VERAPAMIL;

ADENOCARCINOMA; ANOREXIA; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG METABOLISM; DYSPNEA; EXPERIENCE; EYE TOXICITY; FATIGUE; HUMAN; LUNG CANCER; NAUSEA; PATIENT; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SMOKING; STOMATITIS; SURVIVAL;

EID: 24944476953     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200504040-00004     Document Type: Review

References (29)

1. American Cancer Society. Cancer facts & figures 2005 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf [Accessed 2005 Jul 21]
2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Nov 2003 Sub (1973-2001) [online]. Available from URL: www.seer.cancer.gov [Accessed 2004 Aug 20]
3. National Cancer Institute. Non-small cell lung cancer treatment [online]. Available from URL: http://www.cancer.gov [Accessed 2004 Jul 30]
4. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996; 32A (12): 2070-4
5. Pavelic K, Banjac Z, Pavelic J, et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993 Jul; 13 (4): 1133-7
6. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998; 77 (4): 663-9
7. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995 Jul; 19 (3): 183-232
8. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003 Jun; 30 (3 Suppl. 7): 34-46
9. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997 Nov; 57: 4838-48
10. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291 (2): 739-48
11. Dullea RG, Barbacci EG, Miller PE, et al. Induction of apoptosis by CP 358,774, an inhibition of epidermal growth factor receptor tyrosine kinase, in combina-tion with cisplatin [abstract no. 2550]. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research; 2000 Apr 1-5; San Francisco (CA), 401
12. Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004 Jun; 15 (5): 503-12
13. Dai Q, Ling YH, Lia M, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005 Feb 15; 11 (4): 1572-8
14. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005 Jan 1; 65 (1): 226-35
15. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 Sep 7; 101 (36): 13306-11
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 Jun 4; 304 (5676): 1497-500
17. Tran HT, Zinner R, Blumenschein GR, et al. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer [abstract no. 2050]. 2004 ASCO Annual Meeting [online]. Availa-ble from URL: http://www.asco.org [Accessed 2005 Jul 25]
18. Abbas R, Fettner S, Riek M, et al. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects [abstract no. 548]. 2003 ASCO Annual Meeting [online]. Available from URL: http://www.asco.org [Accessed 2005 Jul 25]
19. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001 Jul; 19: 3267-79
20. Mita MM, Patnaik A, Hammond LA, et al. Phase I, pharmacokinetic and biologic study of erlotinib (OSI-774) in combination with paclitaxel and carboplatin in advanced solid malignancies [abstract no. 837]. 2003 ASCO Annual Meeting [online]. Available from URL: http://www.asco.org [Accessed 2005 Jul 25]
21. Rakhit A, Fettner S, Davis S, et al. Lack of pharmacokinetic interaction between erlotinib, docetaxel and capecitabine in breast cancer patients [abstract no. 373]. Eur J Cancer Supplements 2003 Sep; 1 (5): 115
22. Lu J, Eppler SM, Lum BL, et al. A population pharmacokinetic (PK) model for erlotinib (E), a small molecule inhibitor of the epidermal growth factor receptor (EGFR) [abstract no. 2032]. J Clin Oncol 2005 Jun 1; 23 Suppl. 16: 2032
23. Genentech Inc. Tarceva™ package insert. [online]. Available from URL: http:// www.fda.gov/cder/foi/label/2004/021743lbl.pdf [Accessed 2005 Jul 20]
24. Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin Oncol 2003 Jun; 30 (3 Suppl. 7): 25-33
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-32
26. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004 Aug; 22 (16): 3238-47
27. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005 Jul 14; 353 (2): 133-44
28. US Department of Health and Human Services. Tarceva (erlotinib) approval letter [online]. Available from URL: http://www.fda.gov/cder/foi/appletter/2004/ 21743ltr.pdf [Accessed 2005 Jul 20]
29. European Medicines Agency Committee for Medicinal Products for Human Use. Summary of opinion for Tarceva [online]. Available from URL: http://www.emea.eu.int/pdfs/human/opinion/13384605en.pdf [Accessed 2005 Jul 20]